XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development $ 0.0   $ 5.0     $ 0.0 $ 5.0      
Revenues 378.2   288.9     688.8 525.5      
Collaborative Arrangement | Heptares                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development               $ 100.0    
Research and development 30.0                  
Potential milestone payments 2,600.0         2,600.0        
Collaborative Arrangement | Takeda                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development                 $ 120.0  
Potential milestone payments 1,900.0         1,900.0        
Collaborative Arrangement | Idorsia                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development                 $ 45.0  
Potential milestone payments 1,700.0         1,700.0        
Collaborative Arrangement | Xenon                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development                   $ 36.2
Research and development   $ 7.3           $ 5.4    
Potential milestone payments 1,700.0         1,700.0        
Upfront payment                   $ 50.0
Share price (in USD per share)   $ 31.855           $ 19.9755   $ 14.196
Fair value of equity securities               $ 4.6   $ 14.1
Milestone payment   $ 15.0           $ 10.0    
Equity securities, stock price   $ 7.7                
Collaborative Arrangement | Xenon | Common Stock                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Sale of stock (in shares)   0.3           0.3   1.4
Collaborative Arrangement | Voyager                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Acquired in-process research and development       $ 5.0 $ 113.1          
Potential milestone payments 1,300.0         1,300.0        
Upfront payment                   $ 165.0
Share price (in USD per share)                   $ 11.9625
Fair value of equity securities                   $ 54.7
Collaborative Arrangement | Voyager | Common Stock                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Sale of stock (in shares)                   4.2
Collaborative Arrangement | BIAL                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential milestone payments 75.0         75.0        
Collaborative Arrangement | MTPC                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential milestone payment receipts 30.0         $ 30.0        
Revenues 20.0                  
Collaborative Arrangement | MTPC | Minimum | Patents                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Patent term           10 years        
Collaborative Arrangement | AbbVie                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential milestone payment receipts 366.0         $ 366.0        
Collaborative Arrangement | AbbVie | Minimum | Patents                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Patent term           10 years        
Collaborative Arrangement | Royalty | AbbVie                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Revenues $ 5.2   $ 5.9     $ 9.4 $ 10.4